Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Margetuximab - MacroGenics

Drug Profile

Margetuximab - MacroGenics

Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MGAH-22

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Raven biotechnologies
  • Developer GC Pharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II/III Gastric cancer; Oesophageal cancer
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 22 Oct 2019 Efficacy and Adverse events data from the phase III SOPHIA trial in Breast Cancer presented released by MacroGenics
  • 30 Sep 2019 Efficacy data from a phase II in advanced HER2-positive gastroesophageal adenocarcinoma presented at the European Society for Medical Oncology Annual Congress (ESMO-2019)
  • 27 Sep 2019 Phase-II/III clinical trials in Gastric cancer (Combination therapy, First-line therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT04082364)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top